Literature DB >> 17567119

Structural insight into the pharmacophore pocket of human glutamate carboxypeptidase II.

Cyril Barinka1, Miroslava Rovenská, Petra Mlcochová, Klára Hlouchová, Anna Plechanovová, Pavel Majer, Takashi Tsukamoto, Barbara S Slusher, Jan Konvalinka, Jacek Lubkowski.   

Abstract

Inhibition of glutamate carboxypeptidase II (GCPII) has been shown to be neuroprotective in multiple preclinical models in which dysregulated glutamatergic transmission is implicated. Herein, we report crystal structures of the human GCPII complexed with three glutamate mimetics/derivatives, 2-(phosphonomethyl)pentanedioic acid (2-PMPA), quisqualic acid (QA), and L-serine O-sulfate (L-SOS), at 1.72, 1.62, and 2.10 A resolution, respectively. Despite the structural differences between the distal parts of the inhibitors, all three compounds share similar binding modes in the pharmacophore (i.e., S1') pocket of GCPII, where they are stabilized by a combination of polar and van der Waals interactions. The structural diversity of the distal parts of the inhibitors leads to rearrangements of the S1' site that are necessary for efficient interactions between the enzyme and an inhibitor. The set of structures presented here, in conjunction with the available biochemical data, illustrates a flexibility of the GCPII pharmacophore pocket and highlights the structural features required for potent GCPII inhibition. These findings could facilitate the rational structure-based drug design of new GCPII inhibitors in the future.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17567119     DOI: 10.1021/jm070133w

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  30 in total

Review 1.  GCPII imaging and cancer.

Authors:  C A Foss; R C Mease; S Y Cho; H J Kim; M G Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

2.  A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules.

Authors:  Andrew X Zhang; Ryan P Murelli; Cyril Barinka; Julien Michel; Alexandra Cocleaza; William L Jorgensen; Jacek Lubkowski; David A Spiegel
Journal:  J Am Chem Soc       Date:  2010-09-15       Impact factor: 15.419

Review 3.  PET imaging in prostate cancer: focus on prostate-specific membrane antigen.

Authors:  Ronnie C Mease; Catherine A Foss; Martin G Pomper
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

Review 4.  Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer.

Authors:  C Bařinka; C Rojas; B Slusher; M Pomper
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

5.  Structural and biochemical characterization of the folyl-poly-γ-l-glutamate hydrolyzing activity of human glutamate carboxypeptidase II.

Authors:  Michal Navrátil; Jakub Ptáček; Pavel Šácha; Jana Starková; Jacek Lubkowski; Cyril Bařinka; Jan Konvalinka
Journal:  FEBS J       Date:  2014-06-17       Impact factor: 5.542

Review 6.  Advances in understanding the peptide neurotransmitter NAAG and appearance of a new member of the NAAG neuropeptide family.

Authors:  Joseph H Neale; Rafal T Olszewski; Daiying Zuo; Karolina J Janczura; Caterina P Profaci; Kaleen M Lavin; John C Madore; Tomasz Bzdega
Journal:  J Neurochem       Date:  2011-07-01       Impact factor: 5.372

7.  Interactions between human glutamate carboxypeptidase II and urea-based inhibitors: structural characterization.

Authors:  Cyril Barinka; Youngjoo Byun; Crystal L Dusich; Sangeeta R Banerjee; Ying Chen; Mark Castanares; Alan P Kozikowski; Ronnie C Mease; Martin G Pomper; Jacek Lubkowski
Journal:  J Med Chem       Date:  2008-12-25       Impact factor: 7.446

8.  Chemical control over immune recognition: a class of antibody-recruiting small molecules that target prostate cancer.

Authors:  Ryan P Murelli; Andrew X Zhang; Julien Michel; William L Jorgensen; David A Spiegel
Journal:  J Am Chem Soc       Date:  2009-12-02       Impact factor: 15.419

Review 9.  Nanoformulation of natural products for prevention and therapy of prostate cancer.

Authors:  Vanna Sanna; Imtiaz A Siddiqui; Mario Sechi; Hasan Mukhtar
Journal:  Cancer Lett       Date:  2012-11-29       Impact factor: 8.679

10.  Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer.

Authors:  Steve Y Cho; Kenneth L Gage; Ronnie C Mease; Srinivasan Senthamizhchelvan; Daniel P Holt; Akimosa Jeffrey-Kwanisai; Christopher J Endres; Robert F Dannals; George Sgouros; Martin Lodge; Mario A Eisenberger; Ronald Rodriguez; Michael A Carducci; Camilo Rojas; Barbara S Slusher; Alan P Kozikowski; Martin G Pomper
Journal:  J Nucl Med       Date:  2012-12       Impact factor: 10.057

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.